<?xml version="1.0" encoding="UTF-8"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-10-19T00:02:42Z</responseDate><request verb="GetRecord" identifier="oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/10260" metadataPrefix="oai_dc">https://ebyu-rdlopen.rawdatalibrary.net/oai/request</request><GetRecord><record><header><identifier>oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/10260</identifier><datestamp>2026-10-18T21:13:08Z</datestamp><setSpec>openaire</setSpec><setSpec>driver</setSpec><setSpec>com_ebyu_10000</setSpec><setSpec>col_ebyu_10001</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:title>Understanding the relationship between lung GABAA receptors and aquaporin-1: a new therapeutic approach for acute lung injury</dc:title><dc:creator>Halici, Hamza</dc:creator><dc:creator>Karakoy, Zeynep</dc:creator><dc:creator>Cadirci, Elif</dc:creator><dc:creator>Halici, Zekai</dc:creator><dc:creator>Ozdemir, Bengul</dc:creator><dc:creator>Toktay, Erdem</dc:creator><dc:subject>Acute lung injury</dc:subject><dc:subject>Aquaporin-1</dc:subject><dc:subject>Diazepam</dc:subject><dc:subject>GABA&lt;sub&gt;A&lt;/sub&gt;</dc:subject><dc:subject>Animals</dc:subject><dc:subject>Aquaporin 1</dc:subject><dc:subject>Disease Models, Animal</dc:subject><dc:subject>Flumazenil</dc:subject><dc:subject>GABA Modulators</dc:subject><dc:subject>Interleukin-1beta</dc:subject><dc:subject>Interleukin-6</dc:subject><dc:subject>Lipopolysaccharides</dc:subject><dc:subject>Lung</dc:subject><dc:subject>Male</dc:subject><dc:subject>Rats</dc:subject><dc:subject>Rats, Wistar</dc:subject><dc:subject>Receptors, GABA-A</dc:subject><dc:subject>Tumor Necrosis Factor-alpha</dc:subject><dc:subject>4 aminobutyric acid A receptor</dc:subject><dc:subject>interleukin 1beta</dc:subject><dc:subject>interleukin 6</dc:subject><dc:subject>lipopolysaccharide</dc:subject><dc:subject>tumor necrosis factor</dc:subject><dc:subject>Aqp1 protein, rat</dc:subject><dc:subject>benzodiazepine receptor affecting agent</dc:subject><dc:subject>animal experiment</dc:subject><dc:subject>animal model</dc:subject><dc:subject>animal tissue</dc:subject><dc:subject>Article</dc:subject><dc:subject>artificial ventilation</dc:subject><dc:description>Background: This study aimed to investigate the effects of the GABAA receptor and the potential relationship between GABA/ GABAA receptor signalling and aquaporin-1 in acute lung injury (ALI). Methods: Fifty-six male Wistar albino rats (220–240 g) were divided into seven groups. Two groups received intraperitoneal diazepam at 5 or 10 mg/kg. In two other groups, 0.1 mg/kg flumazenil was administered five minutes after diazepam. Thirty minutes after the final treatment, all groups except the healthy controls were subjected to an LPS- induced ALI model. Lung tissue were collected 24 h after LPS administration and analysed using histopathological, molecular, and biochemical methods. Results: In the present study, it was found that aquaporin-1, which plays an important regulatory role in LPS-damaged lung tissue, decreased and the weight of lung tissue increased in wet/dry analysis of a murine model of ALI. The levels of IL-1β, IL-6, and TNF-α were found to be elevated. Additionally, in groups treated with the GABAA receptor modulator diazepam, the levels of these inflammatory cytokines were significantly reduced and in parallel a significant increase in aquaporin-1 expression was observed. Conclusion: Diazepam, acting as a GABAA receptor modulator, may alleviate ALI by reducing inflammation and enhancing aquaporin-1 expression via GABAA receptor activation. © The Author(s) 2026.</dc:description><dc:publisher>BioMed Central Ltd</dc:publisher><dc:date>2026</dc:date><dc:type>Article</dc:type><dc:identifier>https://rdlopen.rawdatalibrary.net/r/ebyu/10260</dc:identifier><dc:identifier>https://doi.org/10.1186/s12890-026-04301-3</dc:identifier><dc:identifier>1471-2466</dc:identifier><dc:language>en</dc:language><dc:relation>BMC Pulmonary Medicine</dc:relation><dc:rights>info:eu-repo/semantics/openAccess</dc:rights><dc:type>info:eu-repo/semantics/article</dc:type><dc:identifier>https://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/10260</dc:identifier></oai_dc:dc></metadata></record></GetRecord></OAI-PMH>